Quebec News Tribune – Lifestyle
Author:
UroGen Pharma Ltd.
UroGen Pharma to Present at Upcoming Investor Conferences
May 7, 2026
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
May 7, 2026
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
April 29, 2026
UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer
April 8, 2026
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
March 30, 2026
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
March 30, 2026
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
March 13, 2026